Official Title
Phase 3, Multicenter, Parallel, Randomized, Single-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Nitazoxanide 600 Mg Administered Twice Daily, in the Outpatient Treatment of COVID-19 and Influenza
Brief Summary

2. Participants will: - Take nitazoxanide 600mg (or placebo) orally twice daily for 7 days, for a total of 14 doses. - Visit the clinic on the 7th day of treatment for a check-up and safety tests. - Keep a diary of their symptoms and other medications used

Detailed Description

Not Provided

Not yet recruiting
COVID 19
Influenza

Drug: Nitazoxanide 600Mg Oral Tablet / placebo oral tablet

1 tablet every 12 hours

Eligibility Criteria

Inclusion Criteria:

- Signed informed consent form;

- Male or female;

- Age ≥ 18 years;

- COVID-19 or influenza diagnosed by rapid test, with symptom onset less than 48 hours
ago;

- Clinical condition compatible with outpatient treatment.

Exclusion Criteria:

- Known hypersensitivity to nitazoxanide;

- History of cardiomyopathies, hepatopathies, or nephropathies;

- Antineoplastic treatment with chemotherapy or radiotherapy;

- Severe autoimmune diseases with immunosuppression;

- Transplant recipients;

- Any uncompensated systemic disease at the investigator's discretion;

- Participation in clinical studies in the last 12 months;

- Pregnant or breastfeeding individuals;

- Suspected bacterial coinfection or prescription of antibiotic therapy at enrollment;

- Diagnosis of neurological disease (traumatic brain injury, stroke, Parkinson's
disease, Alzheimer's disease, other dementias);

- Diagnosis of developmental disorder (ADHD, ASD, learning disabilities, intellectual
disability, Rett syndrome);

- Significant hearing or vision impairment.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Locations

Not Provided

Not Provided

Farmoquimica S.A.
NCT Number
Keywords
Nitazoxanide
outpatient treatment
MeSH Terms
COVID-19
Influenza, Human
Nitazoxanide